HUTCHISON CHINA MED. Stock London S.E.
Stocks
Pharmaceuticals
OTC Markets Traded| Market Cap | 2.18B 1.87B 1.75B 1.6B 3B 209B 3.04B 20.64B 8.05B 105B 8.18B 8.01B 346B | P/E 2026 * |
62x | P/E 2027 * | 58.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.34B 1.15B 1.07B 983M 1.85B 128B 1.87B 12.69B 4.95B 64.41B 5.03B 4.92B 213B | EV / Sales 2026 * |
2.21x | EV / Sales 2027 * | 1.88x |
| Free-Float |
61.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HUTCHISON CHINA MED.
| 1 day | -2.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Chig Fung Cheng
CEO | Chief Executive Officer | 59 | 2025-08-24 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 61 | 2021-12-31 |
Karen Atkin
COO | Chief Operating Officer | 60 | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Edith Shih
BRD | Director/Board Member | 74 | 2005-12-31 |
Chig Fung Cheng
BRD | Director/Board Member | 59 | 2010-12-31 |
Wei Guo Su
BRD | Director/Board Member | 68 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.79% | -0.24% | - | - | 2.18B | |
| +0.88% | +6.38% | +76.40% | +126.75% | 1,119B | |
| +1.07% | +3.80% | +50.73% | +62.78% | 651B | |
| +1.20% | +6.21% | +25.81% | +78.74% | 468B | |
| +1.02% | +5.77% | +43.63% | +48.43% | 374B | |
| +0.85% | +4.07% | +24.97% | +40.58% | 302B | |
| +1.26% | +6.81% | +2.27% | +14.41% | 259B | |
| +1.88% | +5.81% | +49.57% | +70.53% | 238B | |
| +1.59% | +2.09% | -17.33% | -52.62% | 208B | |
| +1.87% | +5.61% | +27.32% | +91.38% | 181B | |
| Average | +0.88% | +4.97% | +31.49% | +53.44% | 422.21B | |
| Weighted average by Cap. | +1.14% | +5.09% | +44.26% | +72.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 606M 519M 486M 445M 835M 58.02B 846M 5.74B 2.24B 29.14B 2.28B 2.23B 96.4B | 689M 590M 552M 505M 948M 65.89B 961M 6.52B 2.54B 33.1B 2.59B 2.53B 109B |
| Net income | 48.09M 41.2M 38.55M 35.29M 66.22M 4.6B 67.1M 455M 178M 2.31B 181M 177M 7.65B | 65.88M 56.43M 52.8M 48.33M 90.71M 6.3B 91.9M 624M 243M 3.17B 247M 242M 10.47B |
| Net Debt | -839M -719M -673M -616M -1.16B -80.31B -1.17B -7.95B -3.1B -40.35B -3.15B -3.08B -133B | -885M -758M -709M -649M -1.22B -84.66B -1.23B -8.38B -3.27B -42.53B -3.32B -3.25B -141B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
